Iovance Biotherapeutics Releases Positive Clinical Data for Lifileucel in Advanced Melanoma

Source: Pharmacy Times, June 2022

Analysis included a 29% objective response rate in cohort 4 of the C-144-01 study, the company says.

Iovance Biotherapeutics announced clinical results from its C-144-01 clinical study in individuals with advanced, either metastatic or unresectable, melanoma who progressed on prior anti-PD-1/L1 therapy, and if BRAF-mutation positive, also on prior BRAF or BRAD.MEK inhibitor therapy.

“Treatment of melanoma patients after failure of anti-PD-1 therapy remains a critical unmet medical need without an approved therapeutic option. Available care for metastatic melanoma patients in this setting is chemotherapy, which has been reported to offer a 4% to 10% response rate with a very short median duration of response,” Friedrich Graf Finckenstein, MD, chief medical officer of Iovance, said in a statement.